A Phase I, First-in-Human Single Center Study in Healthy Adult Volunteers to Assess the Gastric Gluten-Degradation Activity of PvP001
Phase of Trial: Phase I
Latest Information Update: 21 Feb 2019
Price : $35 *
At a glance
- Drugs KumaMax (Primary)
- Indications Coeliac disease
- Focus Adverse reactions; First in man; Therapeutic Use
- 10 Feb 2019 Status changed from recruiting to discontinued.
- 25 Oct 2018 Planned primary completion date changed from 30 Nov 2018 to 30 May 2019.
- 26 Jul 2018 New trial record